CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity.
| Institute |
|---|
| Netherlands Cancer Institute |
| SKU: | 154781 |
|---|---|
| Product description: | CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. |
| Alternate name: | B-lymphocyte antigen CD2 |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 35 kDa |
| Immunogen: | Daudi cells (Burkitt lymphoma) |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 154781 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell biology; Immunology |
| Application: | ELISA ; FACS ; IP |
| Target: | CD20 |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Hooijberg et al. 1996. Hybridoma. 15(1):23-31. PMID: 9064283. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.